Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine
نویسندگان
چکیده
منابع مشابه
Long-term Remission Over Six Years for a Patient with Recurrent Glioblastoma Treated with Cediranib/Lomustine.
Cediranib is an orally available, pan-VEGFR tyrosine kinase inhibitor. A previous Phase III study of patients with recurrent glioblastoma treated with this drug did not meet the primary end of progressive-free survival (PFS). We identified one patient, a 57-year-old Caucasian female who, following surgery in October 2008 and concurrent temozolomide and radiation therapy from November 8, 2008, t...
متن کاملComplete Remission and Long Term Survival in Recurrent Malignant Glioblastoma Treated with Fotemustine Monotherapy: A Case Report
Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. Conventional therapies are considered palliative and long-term progression-free survival remains low for most GBM patients even after surgical excision, concomitant radiotherapy and/or chemotherapy with nitrosoureas or Temozolomide. We report the case of a 47-year-old man who presented worsening headache over a month, acco...
متن کاملLong Term Remission of a Primary Intracerebral Hodgkin Lymphoma in a Patient Previously Treated With Azathioprine
Primary central nervous system (CNS) lymphoma is a rare form of primary brain neoplasm, in which ninety percent of cases are diffuse large B-cell lymphoma. HL involving the CNS is a rare event happening most of them in the context of relapsed systemic disease [1,2]. Primary CNS-hodgkin lymphoma (CNS-HL) is very rare, occurring in less than 0.2% of all HL cases [3], and it has been poorly report...
متن کاملLong-term survival of a patient with glioblastoma.
gliomas and has a median survival of 13.6 months even with aggressive surgical resection, radiation and chemotherapy1. This dismal prognosis is compounded by the failure of novel therapies to yield more than minimal prognostic improvements. A major advance was adjuvant temozolamide treatment but this increased median survival in multi-centre trials by only 2.5 months2-4. Prognostic indicators h...
متن کاملlong-term survival of six patients with glioblastoma multiforme: case series and review of the literature
the median overall survival in glioblastoma multiforme is usually less than one year. long-term survival is rare and is seen in only 3%-6% of gbm patients. the present study reports the characteristics and treatment outcomes of six cases of glioblastoma multiforme with long-term survival. a literature review is also presented. between 1990 and 2008, 217 glioblastoma multiforme patients have bee...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cureus
سال: 2016
ISSN: 2168-8184
DOI: 10.7759/cureus.460